Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jules C Hancox

Showing results (81-90 of 221) with videos related to

Pageof 23
Sort By:
Therapeutic Advances in Infectious Disease|August 29, 2014
A novel genetic modifier for clarithromycin-related cardiac arrhythmia risk?Jules C Hancox, Chunyun Du, Aziza El Harchi, et al.
Biochemical and Biophysical Research Communications|March 14, 2002
Tefluthrin modulates a novel anionic background conductance (I(AB)) in guinea-pig ventricular myocytesJohn J Borg, Jules C Hancox, C Ian Spencer, et al.
Journal of Molecular and Cellular Cardiology|November 18, 2005
Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channelJohn M Ridley, James T Milnes, Jules C Hancox, et al.
British Journal of Pharmacology|September 29, 2011
High potency inhibition of hERG potassium channels by the sodium-calcium exchange inhibitor KB-R7943Hongwei Cheng, Yihong Zhang, Chunyun Du, et al.
Physiological Reports|October 17, 2014
Suppression of the hERG potassium channel response to premature stimulation by reduction in extracellular potassium concentrationDario Melgari, Chunyun Du, Aziza El Harchi, et al.
Plos Computational Biology|December 24, 2011
Increased vulnerability of human ventricle to re-entrant excitation in hERG-linked variant 1 short QT syndromeIsmail Adeniran, Mark J McPate, Harry J Witchel, et al.
Frontiers in Pharmacology|February 11, 2020
An Update on the Structure of hERGAndrew Butler, Matthew V Helliwell, Yihong Zhang, et al.
Physiological Reports|October 6, 2022
QT<sub>c</sub> interval and ventricular action potential prolongation in the Mecp2<sup>Null/+</sup> murine model of Rett syndromeHongwei Cheng, Ian Charles, Andrew F James, et al.
British Journal of Pharmacology|July 4, 2003
Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652James T Milnes, Olivia Crociani, Annarosa Arcangeli, et al.
Journal of Molecular and Cellular Cardiology|July 11, 2015
Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainideDario Melgari, Yihong Zhang, Aziza El Harchi, et al.
Pageof 23

Showing results (81-90 of 221) with videos related to

Sort By:
Pageof 23
Therapeutic Advances in Infectious Disease|August 29, 2014
A novel genetic modifier for clarithromycin-related cardiac arrhythmia risk?Jules C Hancox, Chunyun Du, Aziza El Harchi, et al.
Biochemical and Biophysical Research Communications|March 14, 2002
Tefluthrin modulates a novel anionic background conductance (I(AB)) in guinea-pig ventricular myocytesJohn J Borg, Jules C Hancox, C Ian Spencer, et al.
Journal of Molecular and Cellular Cardiology|November 18, 2005
Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channelJohn M Ridley, James T Milnes, Jules C Hancox, et al.
British Journal of Pharmacology|September 29, 2011
High potency inhibition of hERG potassium channels by the sodium-calcium exchange inhibitor KB-R7943Hongwei Cheng, Yihong Zhang, Chunyun Du, et al.
Physiological Reports|October 17, 2014
Suppression of the hERG potassium channel response to premature stimulation by reduction in extracellular potassium concentrationDario Melgari, Chunyun Du, Aziza El Harchi, et al.
Plos Computational Biology|December 24, 2011
Increased vulnerability of human ventricle to re-entrant excitation in hERG-linked variant 1 short QT syndromeIsmail Adeniran, Mark J McPate, Harry J Witchel, et al.
Frontiers in Pharmacology|February 11, 2020
An Update on the Structure of hERGAndrew Butler, Matthew V Helliwell, Yihong Zhang, et al.
Physiological Reports|October 6, 2022
QT<sub>c</sub> interval and ventricular action potential prolongation in the Mecp2<sup>Null/+</sup> murine model of Rett syndromeHongwei Cheng, Ian Charles, Andrew F James, et al.
British Journal of Pharmacology|July 4, 2003
Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652James T Milnes, Olivia Crociani, Annarosa Arcangeli, et al.
Journal of Molecular and Cellular Cardiology|July 11, 2015
Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainideDario Melgari, Yihong Zhang, Aziza El Harchi, et al.
Pageof 23